Guideline 18.11.2025

Klinik Araştırma Başvurularında Güven Uygulamaları Kılavuzu

EN: This is the official English version published by the authority (TİTCK), imported from the AIFD Legislation Portal archive. The binding text is the official Turkish version.

SB TITCK 05.06.2024 Tarihli Klinik Araştırma Başvurularında Güven Uygulamaları Kılavuzu hk._EN (003)

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 1of7 TurkishMinistryofHealth TurkishMedicinesandMedicalDevicesAgency GUIDELINEONTHERELIANCEPROCEDUREINCLINICALTRIAL APPLICATIONS KAD-KLVZ-024 InitialVersionEffectiveDate 01.09.2022 1 st RevisionEffectiveDate 05.06.2024

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 2of7 TABLEOFCONTENTS PurposeandBasis.....................................................................................................................3 Scope..........................................................................................................................................3 Basis...........................................................................................................................................3 Definitions.................................................................................................................................3 RecognitionofGoodLaboratoryPracticeCertificatesundertheRelianceProcedure....4 RecognitionofGoodLaboratoryPracticeInspectionReportundertheReliance Procedure..................................................................................................................................4 RecognitionoftheInvestigationalMedicinalProductDossierundertheReliance Procedure..................................................................................................................................5 RecognitionofGoodManufacturingPracticeCertificates/Manufacturing AuthorizationCertificatesundertheRelianceProcedure...................................................5 RecognitionofAuxiliaryMedicinalProductUseundertheRelianceProcedure..............6 Effectiveness..............................................................................................................................6 Enforcement..............................................................................................................................6 References.................................................................................................................................7

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 3of7 PurposeandBasis ARTICLE1–(1)ThisGuidelinesetsforththeprinciplesandproceduresforimplementing therelianceprocedureinevaluatingclinicaltrialapplications. (2)ThisGuidelineisissuedbasedontheRegulationonClinicalTrialsofHumanMedicinal Products,publishedforeffectinOfficialGazette#32203of27.05.2023. Scope ARTICLE2–(1)ThisGuidelinecoverstherecognitionundertherelianceprocedureof decisions/reportsissuedbyotherpharmaceuticalauthoritiesorregional/international organizationswhichimplementcomparablestandardstoourAgencyduringreviewofclinical trials,withoutprejudicetotheentitlementoftheAgencyandtheethicscommitteeconcerned torequireadditionalinformationordocuments. Basis ARTICLE3–(1)ThisGuidelineisissuedbasedontheRegulationonClinicalTrialsof HumanMedicinalProducts,publishedforeffectinOfficialGazette#32203of27.05.2023. Definitions ARTICLE4–(1)ForthepurposesofthisGuideline: a)‘Investigationalmedicinalproduct’meansahumanmedicinalproductwhichistested orusedasreferenceinaclinicaltrial,includingplacebo; b)‘Investigationalmedicinalproductdossier’meansacompilationofdataonthe investigationalmedicinalproduct’squality,andmanufacturingandcontrolprocesses anddatafromitsclinicaluse,includingclinicalandnon-clinicalinvestigations; c)‘ApplicationGuideline’meanstheGuidelineonClinicalTrialApplicationsSubmitted tothePresidencyofClinicalTrialsDepartmentofTurkishMedicinesandMedical DevicesAgency(KAD-KLVZ-02); d)‘Outerpackaging’meansthecontainerinwhichtheimmediatepackageisplaced; e)‘Operatingpermit’meansacertificateofauthorizationgrantedbytheAgencyto investigationalsiteswhereclinicalorbioanalyticalcomponentsofPhaseIclinical trialsorbioavailabilityorbioequivalencestudiesarecarriedout; f)‘Reliance’meanstheAgency,informingadecisiononamatterwithinitsjurisdiction, takingintoaccountorrelyingmainlyonanassessmentorotherreviewthathadbeen conductedbyanotherregulatoryauthorityorcredibleinstitution; g)‘Immediatepackaging’meansacontainerorotherformofpackagingindirectcontact withthehumanmedicinalproduct; h)‘Manufacturing(production)’meansweighing,dispensation,primarypackaging, secondarypackaging,andprocessingtofinishedproductofstartingmaterialsusedin themanufacturingprocessofhumanmedicinalproducts,includinginvestigational medicinalproducts,and/oractivesubstances,includingassociatedcontrolsandbatch releaseoperations;

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 4of7 i)‘Agency’meansTurkishMedicinesandMedicalDevicesAgency; j)‘CompetentAuthority’meanscompetentauthorityfoundingmembersofInternational CouncilforHarmonization(ICH)(theUSFoodandDrugAdministration(USFDA), EuropeanMedicinesAgency(EMA),JapaneseMedicinesandMedicalDevices Agency(PMDA))orcompetentauthoritypermanentmembers(NationalMedicines AuthorityofSwitzerland(Swissmedic)andNationalMedicinesAuthorityofCanada (HealthCanada)),theTherapeuticGoodsAdministrationofAustralia(TGA)andthe MedicinesandHealthcareProductsRegulatoryAgencyoftheUK(MHRA). k)‘Regulation’meanstheRegulationonClinicalTrialsofHumanMedicinalProducts, publishedforeffectinOfficialGazette#32203of27.05.2023. (2)ThedefinitionsoftermsprovidedintheRegulationonClinicalTrialsofHuman MedicinalProducts,theGuidelineonGoodClinicalPracticeandotherapplicableregulations alsoapplytothisGuideline. RecognitionofGoodLaboratoryPracticeCertificatesundertheRelianceProcedure ARTICLE5–(1)Preclinicalpharmacologicalandtoxicologicalstudiesmustbeconducted inlinewiththeguidelinesofGoodLaboratoryPractice(GLP),aspublishedinOfficial Gazette#27516of09.03.2010,andtheRegulationonHarmonizationofTestUnits,Good LaboratoryPracticeandInspectionsofStudies. (2)WheretheGLPconcernedisnotpubliclyavailable,theGLPissuedbytheOrganization forEconomicCooperationandDevelopmentshouldbeprovided. RecognitionofGoodLaboratoryPracticeInspectionReportundertheReliance Procedure ARTICLE6–(1)AsdetailedintheApplicationGuideline,theinvestigationalmedicinal productdossiermustincludeastatementconfirmingthattheclinicaltrialsproposedtothe Agencyareconductedinlinewiththerequirementsofgoodclinicalpractice(GCP). Nevertheless,theAgencymay,atitsdiscretion,requireaninspectionreportissuedbyanother healthauthorityconfirmingthatthestudiesareconductedinlinewithGCP,orconductaGCP inspectionitself. (2)UnlessabreachofTurkishregulationshasbeenidentified,theAgencywillnotconducta GCPinspectionprovidedthataGCPinspectionreportbyaCompetentAuthorityforthe clinicaltrialconcernedhasbeensubmitted,establishingthattheinvestigationalsites/studies inspectedorthedatageneratedinthestudyconcernedareconformanttoGCPrequirements. (3)IftheGCPinspectionreportssubmittedwereissuedbyahealthauthorityotherthana CompetentAuthority,theAgencywillgoaheadwithconductingaGCPinspectionaccording totheapplicableguideline.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 5of7 RecognitionoftheInvestigationalMedicinalProductDossierundertheReliance Procedure ARTICLE7–(1)TheRegulationrequiressubmissionofaninvestigationalmedicinal productdossier(IMPD)withaclinicaltrialapplication,compiledinlinewiththe requirementsoftheapplicableguidelinesissuedbytheAgency. (2)ForinvestigationalmedicinalproductswhichareauthorizedbyaCompetentAuthoritybut notinTürkiye,itisnotnecessarytosubmitanIMPDiftheinformationprovidingbasisfor marketingauthorizationhasnotbeenmodified;itissufficienttoprovidethenameofthe marketingauthorizationholderandthemarketingauthorizationnumber,withacopyofthe summaryofproductcharacteristicsoranoverviewofproductcharacteristicsorprescribing information. (3)ForinvestigationalmedicinalproductswhichareauthorizedbyaCompetentauthoritybut notinTürkiye,wheretheinformationprovidingbasisformarketingauthorizationhasbeen modified,itissufficienttosubmittherelevantsectionsoftheIMPD,dependingontheextent ofthemodifications,accordingtotheQualityGuidelines.Insuchcase,theAgencywillnot reviewtheIMPDandrecognizeitasvalid,ifthesameIMPDsubmittedtotheAgency,with thesamedateandversionnumber,hadbeenreviewedandapprovedbyaCompetent Authority,asevidencedbyasignedandapostilledcertificate. (4)ForinvestigationalmedicinalproductswhicharenotauthorizedbyaCompetentAuthority norinTürkiye,itisnecessarytosubmitanIMPD.Insuchcase,theAgencywillnotreview theIMPDandrecognizeitasvalid,ifthesameIMPDsubmittedtotheAgency,withthesame dateandversionnumber,hadbeenreviewedandapprovedbyaCompetentAuthority,as evidencedbyasignedandapostilledcertificate. RecognitionofGoodManufacturingPracticeCertificates/Manufacturing AuthorizationCertificatesundertheRelianceProcedure ARTICLE8–(1)Article12oftheRegulationrequiresassurancethattheinvestigational medicinalproductwasmanufacturedinlinewiththerequirementsofgoodmanufacturing practice(GMP). (2)AsspecifiedintheApplicationGuideline,theclinicaltrialapplicationdossiermust includeeitheramanufacturingauthorizationcertificateoraGMPcertificate. a)ItissufficienttosubmitanAgency-recognizeddocumentorinformation,affirming thattheactivesubstance(s)and,whereapplicable,theintermediate(s)usedinthe manufacturingprocessoftheactivesubstance,aremanufacturedinlinewith internationally-recognizedGMP. b)Forallinvestigationalmedicinalproductstobeusedintheclinicaltrial,the applicationdossiermustincludebatchreleasecertificate(s),batchanalysis/quality controlcertificate(s),andGMPcertificate(s)forthemanufacturingsite(s)whereall manufacturingsteps,exceptouterpackagingandlabeling,areperformed. 1)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteholdingamanufacturingauthorizationcertifiedissuedby theAgency,Annex2totheManufacturingAuthorizationCertificate(activities involvinginvestigationalhumanmedicinalproducts)mustbeavailableforthe investigationalmedicinalproducts;Annex2totheManufacturing AuthorizationCertificatemustcoverallrequisitemanufacturingstepsofthe investigationalmedicinalproduct.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 6of7 2)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroad,asignedandapostilledGMPcertificate,issuedbya competentauthoritypartytoPIC/SandaICH,mustbesubmitted.Wherethe competentauthorityconcerneddoesnotpubliclyrevealinformationabout facilities,areferencenumber/details/certificates(e.g.EudraGMPextract), foraccessingthisinformation,mustbeprovided. 3)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroadandtheGMPcertificatewasissuedbyaauthority otherthanonewhoispartytoPIC/SorICH,asignedandapostilledletterof approvalissuedfortheproposedclinicaltrialbyaCompetentAuthoritymust beprovided,withaformalaffirmationthattheinvestigationalmedicinal producttobeusedintheclinicaltrialinTürkiyeismanufacturedatthesame manufacturingsiteastheonetobeusedinthecountryoftheapproving CompetentAuthority. 4)Wheretheinvestigationalmedicinalproductismanufacturedata manufacturingsiteabroadandtheGMPcertificatesubmittedforthe manufacturingsitewasnotissuedbyacompetentauthoritypartytoPIC/Sor ICH,andthedocumentslistedunderPoint3abovecannotbesubmitted,the AgencywillconductaGMPinspection. c)ItissufficienttosubmitanAgency-recognizedcertificateorinformation,showing conformitytointernationally-recognizedGMPrequirements,forfacilitiesresponsible forbatchrelease,batchanalysis/qualitycontrol,outerpackagingandlabeling operations. RecognitionofAuxiliaryMedicinalProductUseundertheRelianceProcedure ARTICLE9–(1)AccordingtotheRegulation,auxiliarymedicinalproductsmustbe authorizedinTürkiye. (2)Ifjustifiedbytheapplicant,however,theAgencymayacceptuseofhumanmedicinal products,whichareauthorizedbyaCompetentAuthorityandusedinlinewiththeproduct informationprovidingbasisformarketingauthorization,asanauxiliarymedicinalproduct. (3)TheprovisionsmadeinArticles7and8ofthisGuidelinealsoapplytoauxiliarymedicinal products. Effectiveness ARTICLE10–(1)ThisGuidelinewillbecomeeffectiveafterapprovalbytheAgency President. Enforcement ARTICLE11–(1)TheAgencyPresidentwillenforcethisGuideline.

DocumentNumber InitialIssueDate RevisionDate RevisionNumber Page KAD-KLVZ-24 01.09.2022 05.06.2024 01 7of7 References 1.RegulationonManufacturingFacilitiesofHumanMedicinalProducts,publishedin OfficialGazette#30217of21.10.2017. 2.RegulationonMarketingAuthorizationofHumanMedicinalProducts,publishedin OfficialGazette#31686of11.12.2021. 3.RegulationonClinicalTrialsofHumanMedicinalProducts,publishedinOfficialGazette #31686of27.05.2023. 4.GuidelineonChemicalandPharmaceuticalQualityRequirementsforHumanMedicinal ProductsUsedinClinicalTrials 5.GuidelineonQualityRequirementsforBiologicalMedicinalProductsUsedinClinical Trials 6.GuidelineonClinicalTrialApplicationsSubmittedtothePresidencyofClinicalTrials DepartmentofTurkishMedicinesandMedicalDevicesAgency REVISIONHISTORY RevisionNumber RevisionDate RationaleandDescription 01 UpdatedArticles6and8toalignwiththe newRegulation. UpdatedArticles7and9toalignwiththe newRegulation. Reviewedandupdatedtoalignwiththe newRegulation.